Visitors and news

Dr Catherine Sauvaget shared and discussed measures with the IARC colleague’s to fight and prevent cervical cancer and to improve awareness and current knowledge.

This article demonstrates the needs for an update of the European Council recommendations on cancer screening published in 2003 to take into account the introduction of the new tests or protocols (newly defined age ranges for mammography screening, HPV-based cervical cancer screening, fecal immune-chemical test and sigmoidoscopy) and the need to pragmatically assessed the outcomes of recent randomized trials published on screening for lung and prostate cancer. View the article.

Human papillomavirus (HPV) test, self-sampling, and thermal ablation have been developed separately to improve coverage and compliance of cervical cancer screening programmes. In this study, authors evaluated their combinations to explore the optimal cervical cancer screening cascade in the real-world. They found that the combination of PCR HPV test followed by HPV 16/18 triaging on self-collected samples and colposcopy of triage-positive women followed by immediate thermal ablation might be the appropriate screening cascade for rural China. View the article.

Dr Andre Carvalho organized the kick-off meeting for the lung cancer project in collaboration with the N.N. Alexandrov National Cancer Centre of Belarus: “Development and implementation of a pilot program for lung cancer screening in Belarus (BELUNGS)”

The Screening Group (SCR) team is deeply saddened by the demise of Doctor B. M. Nene, the founder of the Ashwini Rural Cancer Research and Relief Society (ARCRRS) and the Nargis Dutt Memorial Cancer Hospital (NDMCH), Barshi, India. Dr. Nene died on Sunday 19 January 2020 in Pune, India. He was an accomplished clinician, great researcher and above all a wonderful human being. We express our deepest condolences to Ms. Nene and family and pray for eternal peace for the great soul of our beloved Dr. Nene.
Read the IARC news

Dr Partha Basu, Dr Sauvaget and Dr Selmouni in collaboration with the Lalla Salma Foundation met Professor Ndom from the Cameroon Ministry of Health and representatives from partners institutions to discuss the implementation of Care4Afrique project: implementation of a pilot cervical cancer screening programme based on a single-visit approach. This project is also currently implemented in Benin, Côte d’Ivoire and Senegal.

Dr Partha Basu, Head of the IARC Screening Group, presents an overview of the worldwide burden of cervical cancer and how IARC is working to eliminate this preventable disease. Current research projects include a project assessing vaccine efficacy, projects to improve access to vaccination and screening, and projects to improve treatment of cervical precancer in low- and middle-income settings. All of these contribute to WHO’s Cervical Cancer Elimination Initiative and provide evidence to support guidelines and policy to. Watch video.

Dr Partha Basu presented within the framework of the ECHO project, the medical digital Indian platform attended by Indian gynaecologists, a virtual seminar about Preventing Errors on Colposcopy: Limitations of colposcopy and quality assurance.

Throughout January, the International Agency for Research on Cancer (IARC) will mark Cervical Cancer Awareness Month with a series of posts, including tweets, interviews, and infographics. Stay tuned to the IARC website, www.iarc.fr, the IARC Twitter account, @IARCWHO, and the IARC YouTube channel, IARC WHO, during January to learn more about cervical cancer and the worldwide initiative to eliminate this disease as a public health problem. Read the IARC news

The Screening Group is delighted to present the findings of this systematic review published in Vaccine. This review supports the premise that one HPV vaccine dose may be as effective in preventing HPV infection as multi-dose schedules in healthy young women. However, it also highlights the paucity of available evidence from purpose-designed, prospectively-randomised trials. Results from ongoing clinical trials assessing the efficacy and immunogenicity of single-dose HPV vaccination compared to currently-recommended schedules are awaited. View the article.